A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 11
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : RE
Long Form : Remogliflozin etabonate
No. Year Title Co-occurring Abbreviation
2015 Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment. SGLT2
2015 Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. SGLT2
2015 Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. ---
2015 Remogliflozin etabonate : a novel SGLT2 inhibitor for treatment of diabetes mellitus. HbA1c, SGLT2
2015 Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. HbA1c, SGLT2
2014 Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. SE, SGLT2
2013 First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. PK, SGLT2, SGLT2, T2DM, UGE
2013 Regional gastrointestinal delivery of remogliflozin etabonate in humans. ---
2013 Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. SGLT2, T2DM, UGE
10  2012 Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. SGLT2, T2DM, UGE
11  2012 Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. ---